192635-89-5

Upstream product

• 186095-24-9 N-(2-Bromopropionyl)-glycine benzyl ester 
• 122555-91-3 1,4,7-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane 
• 294-90-6 1,4,7,10-tetraazacyclododecan 
• 10045-25-7 1,4,7,10-tetraazacyclododecane tetrahydrochloride 
• 5437-45-6 Benzyl bromoacetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 244219-73-6 (1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid benzyl ester 

Downstream Products

• 170908-81-3 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimidyl ester) 
• 1006711-90-5 2,2',2''-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid 
• 1613382-10-7 tri-tert-butyl 2,2',2''-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 819869-77-7 tri-tert-butyl 2,2’,2”-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 137076-54-1 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid 

Relevant academic research and scientific papers

Multivalent Siderophore–DOTAM Conjugates as Theranostics for Imaging and Treatment of Bacterial Infections

There is a strong need to better diagnose infections at deep body sites through noninvasive molecular imaging methods. Herein, we describe the synthesis and characterization of probes based on siderophore conjugates with catechol moieties and a central DO

Ligand taking indocyanine green derivative as carrier as well as preparation method and application of ligand

The invention discloses a ligand taking an indocyanine green derivative as a carrier as well as a preparation method and application of the ligand. When the ligand is chelated with paramagnetic metal ions, an NIR/MRI multi-mode contrast agent is obtained, when the ligand is chelated with radioactive metal ions, an NIR/PET multi-mode contrast agent is obtained, and the obtained contrast agents can be used for diagnosis of various tumors, especially liver cancer. Meanwhile, the contrast agents are good in water solubility and low in toxicity, mutual verification of multiple contrast modes is achieved, diagnosis information is enriched, diagnosis precision is improved, and a feasible novel contrast agent is provided for early diagnosis of tumors clinically.

NIR/PET bimodal contrast agent, and preparation method and application thereof

The invention discloses a near infrared and positron emission computed tomography (NIR)/positron emission tomography (PET) bimodal contrast agent, and a preparation method and application thereof. The NIR/PET bimodal contrast agent is obtained by taking an optimized indocyanine green derivative as a carrier and connecting a PET signal molecule. The contrast agent can be used for near-infrared imaging and has PET imaging capability; and meanwhile, the contrast agent is good in water solubility and low in toxicity, near-infrared and PET images verify each other, diagnosis information is enriched, and the contrast agent has the potential of becoming a novel tumor contrast agent.

NIR/MRI bimodal contrast agent, and preparation method and application thereof

The invention discloses a near infrared imaging and nuclear magnetic resonance imaging (NIR)/MRI bimodal contrast agent, and a preparation method and application thereof. The NIR/MRI bimodal contrast agent is obtained by taking an optimized indocyanine green derivative as a carrier and connecting an MRI signal molecule. The contrast agent can be used for near-infrared imaging and also has an MRI imaging capability; and meanwhile, water solubility is good, toxicity is low, near-infrared and MRI images verify each other, diagnosis information is enriched, and the contrast agent has the potential of becoming a novel tumor contrast agent.

Time-Resolved Terbium-Based Probe for the Detection of Zinc(II) Ions: Investigation of the Formation of a Luminescent Ternary Complex

Because of their unique photochemical and photophysical properties, luminescent lanthanide-based complexes have long captivated chemists. In recent years, the number of reports of luminescent lanthanide complex-based probes for monitoring of biological an

Method for preparing DOTA derivative organic ligand which is a precursor DOTA-tris(tBu ester) of hypoxic tissue contrast agent DOTA-Ni with significant cost advantage in the preparation

The present invention relates to a method for preparing DOTA derivative organic ligand, which uses benzyl bromoacetate as one of the reactants in the synthesis process. Firstly, the starting materials 1,4,7,10-tetrazacyclododecane, sodium acetate and tert

1,4,7,10-TETRAZACYCLODODECANE BASED AGENTS TO TARGET BACTERIA AND ITS USE

The present invention relates to new compounds comprising a siderophore moiety as well as a core structure able to chelate a metal ion. Optionally, the compounds may have additionally a moiety with a functional element including a marker molecule, a bioactive agent, an activity based probe suitable to monitor the aberrant expression or activity of proteins involved in the initiation and progression of bacterial infection, or a compound useful for bacterial inhibition. In a further aspect, the present invention provides a pharmaceutical composition containing said compound, for example, said pharmaceutical composition is an antibiotic. Additionally, the present invention relates to the use of said compounds in diagnostic methods, in particular, imaging methods including SPEC, PET or MRI. In an embodiment of the present invention, the compound is part of a theranostic composition having both, therapeutic as well as diagnostic activities.

DOTAM DERIVATIVES FOR THERAPEUTIC USE

The present invention relates to A compound of the formula I, in any of their stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, and the pharmaceutically acceptable salts thereof, (I) wherein M is absent or present and a positively ch

Design, synthesis, and in vitro evaluation of a binary targeting MRI contrast agent for imaging tumor cells

A binary targeting vector that consists of peptide sequences of Arg-Gly-Asp (RGD) and Asn-Gly-Arg (NGR) motifs has been designed and synthesized using solid-phase peptide synthesis procedure. The vector is then coupled with Gd-DOTA to work as a targeting

CANCER IMAGING AND TREATMENT

A compound, or a pharmaceutically acceptable salt or ester thereof, comprises the structure: [in-line-formulae][(P1-S1j)p-L-(S2q-P2)r]t [/in-line-formulae] wherein: P1 and P2, which may be the same or